{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:53:44Z","timestamp":1785772424693,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite considerable therapeutic advances, a\u00a0significant evidence gap remains regarding optimal treatment strategies for cisplatin-unfit patients and whether carboplatin\/paclitaxel represents a\u00a0valid therapeutic alternative. This study investigates the treatment outcomes of patients receiving various platinum-based chemotherapy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between 2012 and 2022, 170 patients with LAHNSCC were included in the analysis. Overall survival (OS) and progression-free survival (PFS), as well as treatment-related toxicities, were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The included patients were treated with intensity-modulated radiotherapy (IMRT) at a\u00a0total dose of 59.4\u201372\u202fGy, along with 5\u20136\u00a0cycles of weekly platinum-based chemotherapy. 130 patients received cisplatin (40\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      BSA), while 40\u00a0patients received carboplatin (AUC\u00a01) and paclitaxel (40\u202fmg\/m\n                      <jats:sup>2<\/jats:sup>\n                      BSA). Median follow-up was 32\u00a0months. No significant difference was observed in median PFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.14; HR 0.74 [0.44\u20131.26]) nor OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.11; HR 0.62 [0.36\u20131.10]). Subgroup analysis showed that especially patients &lt;\u202f65\u00a0years and patients in the adjuvant setting benefit from the use of cisplatin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Definitive and postoperative radiochemotherapy for the treatment of LAHNSCC with concurrent administration of carboplatin\/paclitaxel can be used as a\u00a0safe and effective alternative but only for cisplatin-ineligible patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02579-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:58:47Z","timestamp":1785769127000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Carboplatin\/Paclitaxel can be an effective alternative for cisplatin-ineligible patients with locally advanced HNSCC"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-0430","authenticated-orcid":false,"given":"Stefan","family":"Gravemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jule","family":"Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Steike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Schlusemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armands","family":"Riders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Reinartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rudack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"6","key":"2579_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray\u00a0F, Ferlay\u00a0J, Soerjomataram\u00a0I, Siegel\u00a0RL, Torre\u00a0LA, Jemal\u00a0A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"issue":"10166","key":"2579_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","volume":"393","author":"H Mehanna","year":"2019","unstructured":"Mehanna\u00a0H, Robinson\u00a0M, Hartley\u00a0A et\u00a0al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet 393(10166):51\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(18)32752-1","journal-title":"The Lancet"},{"key":"2579_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","volume":"156","author":"B Lacas","year":"2021","unstructured":"Lacas\u00a0B, Carmel\u00a0A, Landais\u00a0C et\u00a0al (2021) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Clin Transl Radiat Oncol 156:281\u2013293. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.013","journal-title":"Radiother Oncol"},{"issue":"6","key":"2579_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner\u00a0JA, Harari\u00a0PM, Giralt\u00a0J et\u00a0al (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 354(6):567\u2013578. https:\/\/doi.org\/10.1056\/NEJMoa053422","journal-title":"N Engl J Med"},{"issue":"19","key":"2579_CR5","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa032646","volume":"350","author":"JS Cooper","year":"2004","unstructured":"Cooper\u00a0JS, Pajak\u00a0TF, Forastiere\u00a0AA et\u00a0al (2004) Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 350(19):1937\u20131944. https:\/\/doi.org\/10.1056\/NEJMoa032646","journal-title":"N Engl J Med"},{"key":"2579_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00464","volume":"9","author":"P Szturz","year":"2019","unstructured":"Szturz\u00a0P, Cristina\u00a0V, Herrera G\u00f3mez\u00a0RG, Bourhis\u00a0J, Simon\u00a0C, Vermorken\u00a0JB (2019) Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice. Front Oncol 9:464. https:\/\/doi.org\/10.3389\/fonc.2019.00464","journal-title":"Front Oncol"},{"issue":"1","key":"2579_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00066-011-0006-y","volume":"188","author":"F Alongi","year":"2012","unstructured":"Alongi\u00a0F, Bignardi\u00a0M, Garassino\u00a0I et\u00a0al (2012) Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma: Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Strahlenther Onkol 188(1):49\u201355. https:\/\/doi.org\/10.1007\/s00066-011-0006-y","journal-title":"Strahlenther Onkol"},{"issue":"13","key":"2579_CR8","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1200\/JCO.22.00980","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil\u00a0VM, Noronha\u00a0V, Menon\u00a0N et\u00a0al (2023) Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. J\u00a0Clin Oncol 41(13):2350\u20132361. https:\/\/doi.org\/10.1200\/JCO.22.00980","journal-title":"J Clin Oncol"},{"issue":"2","key":"2579_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","volume":"13","author":"J Bourhis","year":"2012","unstructured":"Bourhis\u00a0J, Sire\u00a0C, Graff\u00a0P et\u00a0al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13(2):145\u2013153. https:\/\/doi.org\/10.1016\/S1470-2045(11)70346-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"2579_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ijrobp.2014.12.034","volume":"91","author":"V Budach","year":"2015","unstructured":"Budach\u00a0V, Stromberger\u00a0C, Poettgen\u00a0C et\u00a0al (2015) Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6\u202fGy With Concurrent 5\u2011FU\/Mitomycin\u00a0C Is Superior to HART of 77.6\u202fGy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase\u00a0III Trial. Adv Radiat Oncol 91(5):916\u2013924. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.034","journal-title":"Int J Radiat Oncol"},{"issue":"10","key":"2579_CR11","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1080\/0284186X.2019.1658897","volume":"58","author":"M Saks\u00f8","year":"2019","unstructured":"Saks\u00f8\u00a0M, Andersen\u00a0E, Bentzen\u00a0J et\u00a0al (2019) A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. Acta Oncol 58(10):1495\u20131501. https:\/\/doi.org\/10.1080\/0284186X.2019.1658897","journal-title":"Acta Oncol"},{"issue":"12","key":"2579_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1159\/000494031","volume":"41","author":"S Maring","year":"2018","unstructured":"Maring\u00a0S, Elsayad\u00a0K, Stenner\u00a0M et\u00a0al (2018) Efficacy of Carboplatin\/Paclitaxel-Based Radiochemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck. Oncol Res Treat 41(12):736\u2013743. https:\/\/doi.org\/10.1159\/000494031","journal-title":"Oncol Res Treat"},{"issue":"2","key":"2579_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.21873\/invivo.12769","volume":"36","author":"S Nassif","year":"2022","unstructured":"Nassif\u00a0S, Wichmann\u00a0J, Strube\u00a0D, Vassis\u00a0S, Christiansen\u00a0H, Steinmann\u00a0D (2022) Cisplatin Versus Carboplatin and Paclitaxel in Radiochemotherapy for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma. In Vivo 36(2):821\u2013832. https:\/\/doi.org\/10.21873\/invivo.12769","journal-title":"In Vivo"},{"issue":"1","key":"2579_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0360-3016(00)00408-9","volume":"47","author":"M Suntharalingam","year":"2000","unstructured":"Suntharalingam\u00a0M, Haas\u00a0ML, Conley\u00a0BA et\u00a0al (2000) The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol 47(1):49\u201356. https:\/\/doi.org\/10.1016\/S0360-3016(00)00408-9","journal-title":"Int J Radiat Oncol"},{"issue":"9","key":"2579_CR15","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/hed.27456","volume":"45","author":"J Han","year":"2023","unstructured":"Han\u00a0J, Zakeri\u00a0K, Raab\u00a0G et\u00a0al (2023) Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head Neck 45(9):2207\u20132216. https:\/\/doi.org\/10.1002\/hed.27456","journal-title":"Head Neck"},{"issue":"5","key":"2579_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1634\/theoncologist.2011-0396","volume":"17","author":"G Vlacich","year":"2012","unstructured":"Vlacich\u00a0G, Diaz\u00a0R, Thorpe\u00a0SW et\u00a0al (2012) Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy. The Oncologist 17(5):673\u2013681. https:\/\/doi.org\/10.1634\/theoncologist.2011-0396","journal-title":"The Oncologist"},{"issue":"10","key":"2579_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00066-011-1111-7","volume":"187","author":"R Semrau","year":"2011","unstructured":"Semrau\u00a0R, Temming\u00a0S, Preuss\u00a0SF, Klu\u00dfmann\u00a0JP, Guntinas-Lichius\u00a0O, M\u00fcller\u00a0RP (2011) Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel: A phase II study. Strahlenther Onkol 187(10):645\u2013650. https:\/\/doi.org\/10.1007\/s00066-011-1111-7","journal-title":"Strahlenther Onkol"},{"issue":"S3","key":"2579_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF03215921","volume":"175","author":"A Eckardt","year":"1999","unstructured":"Eckardt\u00a0A, Wildfang\u00a0I, Karstens\u00a0JH (1999) Simultane Radiochemotherapie mit Taxol\/Carboplatin bei fortgeschrittenen operablen Kopf-Hals-Tumoren: Vorl\u00e4ufige Ergebnisse. Strahlenther Onkol 175(S3):11\u201313. https:\/\/doi.org\/10.1007\/BF03215921","journal-title":"Strahlenther Onkol"},{"issue":"18_suppl","key":"2579_CR19","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1200\/jco.2006.24.18_suppl.5507","volume":"24","author":"R Fietkau","year":"2006","unstructured":"Fietkau\u00a0R, Lautenschl\u00e4ger\u00a0C, Sauer\u00a0R et\u00a0al (2006) Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: Results of the German phase III trial ARO 96\u20133. J\u00a0Clin Oncol 24(18_suppl):5507\u20135507. https:\/\/doi.org\/10.1200\/jco.2006.24.18_suppl.5507","journal-title":"J Clin Oncol"},{"issue":"4","key":"2579_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00066-025-02370-7","volume":"201","author":"J Beier","year":"2025","unstructured":"Beier\u00a0J, R\u00fchle\u00a0A (2025) Definitive Radiotherapie mit Cetuximab oder Durvalumab bei Patienten mit einem lokoregion\u00e4r fortgeschrittenen Kopf-Hals-Karzinom und einer Cisplatinkontraindikation (NRG-HN004). Strahlenther Onkol 201(4):475\u2013477. https:\/\/doi.org\/10.1007\/s00066-025-02370-7","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"2579_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/annonc\/mdm088","volume":"18","author":"SS Agarwala","year":"2007","unstructured":"Agarwala\u00a0SS, Cano\u00a0E, Heron\u00a0DE et\u00a0al (2007) Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Facts Views Vis Obgyn 18(7):1224\u20131229. https:\/\/doi.org\/10.1093\/annonc\/mdm088","journal-title":"Ann Oncol"},{"issue":"1","key":"2579_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/COC.0b013e3182019ee3","volume":"35","author":"NE Ready","year":"2012","unstructured":"Ready\u00a0NE, Rathore\u00a0R, Johnson\u00a0TT et\u00a0al (2012) Weekly Paclitaxel and Carboplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol 35(1):6\u201312. https:\/\/doi.org\/10.1097\/COC.0b013e3182019ee3","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2579_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40463-016-0163-1","volume":"45","author":"M Roskies","year":"2016","unstructured":"Roskies\u00a0M, Kay-Rivest\u00a0E, Mascarella\u00a0MA, Sultanem\u00a0K, Mlynarek\u00a0A, Hier\u00a0M (2016) Survival outcomes in patients with oropharyngeal cancer treated with carboplatin\/paclitaxel and concurrent radiotherapy. J\u00a0Otolaryngol - Head Neck Surg 45(1):50. https:\/\/doi.org\/10.1186\/s40463-016-0163-1","journal-title":"J Otolaryngol - Head Neck Surg"},{"issue":"8","key":"2579_CR24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamaoto.2025.1706","volume":"151","author":"M Abousaud","year":"2025","unstructured":"Abousaud\u00a0M, Pamulapati\u00a0S, Rashid\u00a0S et\u00a0al (2025) Radiotherapy With Cisplatin vs Carboplatin Paclitaxel for Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg 151(8):769\u2013769. https:\/\/doi.org\/10.1001\/jamaoto.2025.1706","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"2579_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00761","volume":"10","author":"SH Hanemaaijer","year":"2020","unstructured":"Hanemaaijer\u00a0SH, Kok\u00a0IC, Fehrmann\u00a0RSN et\u00a0al (2020) Comparison of Carboplatin With 5\u2011Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. Front Oncol 10:761. https:\/\/doi.org\/10.3389\/fonc.2020.00761","journal-title":"Front Oncol"},{"issue":"5","key":"2579_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.ijrobp.2023.10.025","volume":"118","author":"A R\u00fchle","year":"2024","unstructured":"R\u00fchle\u00a0A, Weymann\u00a0M, Behrens\u00a0M et\u00a0al (2024) A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation. Adv Radiat Oncol 118(5):1282\u20131293. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.10.025","journal-title":"Int J Radiat Oncol"},{"key":"2579_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.3840","author":"SN Marschner","year":"2025","unstructured":"Marschner\u00a0SN, Lombardo\u00a0E, Haehl\u00a0E et\u00a0al (2025) Outcome Prediction in Older Adults With Head and Neck Cancer Undergoing Chemoradiation. JAMA Otolaryngol Head Neck Surg. https:\/\/doi.org\/10.1001\/jamaoto.2025.3840","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"1","key":"2579_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri\u00a0R, Haddad\u00a0RI, Tao\u00a0Y et\u00a0al (2025) Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med 393(1):37\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2415434","journal-title":"N Engl J Med"},{"key":"2579_CR29","unstructured":"Bourhis J, Auperin A, Borel C, et\u00a0al. NIVOPOSTOP (GORTEC 2018-01): A\u00a0phase\u00a0III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse."},{"key":"2579_CR30","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.radonc.2020.07.032","volume":"151","author":"S Lerch","year":"2020","unstructured":"Lerch\u00a0S, Berthold\u00a0S, Ziemann\u00a0F et\u00a0al (2020) HPV-positive HNSCC cell lines show strongly enhanced radiosensitivity after photon but not after carbon ion irradiation. Clin Transl Radiat Oncol 151:134\u2013140. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.032","journal-title":"Radiother Oncol"},{"issue":"2","key":"2579_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.radonc.2013.03.013","volume":"107","author":"T Rieckmann","year":"2013","unstructured":"Rieckmann\u00a0T, Tribius\u00a0S, Grob\u00a0TJ et\u00a0al (2013) HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Clin Transl Radiat Oncol 107(2):242\u2013246. https:\/\/doi.org\/10.1016\/j.radonc.2013.03.013","journal-title":"Radiother Oncol"},{"issue":"9","key":"2579_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00066-014-0605-5","volume":"190","author":"A Arenz","year":"2014","unstructured":"Arenz\u00a0A, Ziemann\u00a0F, Mayer\u00a0C et\u00a0al (2014) Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol 190(9):839\u2013846. https:\/\/doi.org\/10.1007\/s00066-014-0605-5","journal-title":"Strahlenther Onkol"},{"issue":"62","key":"2579_CR33","doi-asserted-by":"publisher","first-page":"105170","DOI":"10.18632\/oncotarget.22005","volume":"8","author":"F Ziemann","year":"2017","unstructured":"Ziemann\u00a0F, Seltzsam\u00a0S, Dreffke\u00a0K et\u00a0al (2017) Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines. Oncotarget 8(62):105170\u2013105183. https:\/\/doi.org\/10.18632\/oncotarget.22005","journal-title":"Oncotarget"},{"issue":"1","key":"2579_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang\u00a0KK, Harris\u00a0J, Wheeler\u00a0R et\u00a0al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02579-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:58:48Z","timestamp":1785769128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":34,"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02579-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local ethics committee of the University Hospital Muenster (Germany) and the Medical Association Westphalia-Lippe (registration number 2025-686-f-S).","order":1,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the observational study, the need for individual informed consent was waived by the local ethics committee.","order":2,"name":"Ethics","label":"Informed Consent Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.\u00a0Gravemeyer, J.\u00a0Hermanns, D.R.\u00a0Steike, T.\u00a0Schlusemann, M.\u00a0Oberste, A.\u00a0Riders, G.\u00a0Reinartz, C.\u00a0Rudack and H.T.\u00a0Eich declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}